gucag006
Nov 17, 10:37 PM
$LXRX Put things in perspective:
- BMY acquired MyoKardia for the drug Camzyos for
$13B in 2020, and 2 years later it cleared FDA to treat oHCM. Then in 2025 Camzyos failed the P3 trial for nHCM leaving it for oHCM only. Camzyos annual sales from 2023 to '25 are, respectively,
$231M,
$602M and
$1.07.
- Inpefa (Sotagliflozin) has been approved for both HFrEF and the much-more-difficult-to-treat HFpEF.
- Inpefa is leading the pack in preventing HHF and CVD death with NNT=4 vs. NNT~10-20 for other SGLT2 inhibitors and Entresto.
- Sotagliflozin, a dual SGLT1&2 inhibitor, has been approven for HF; being P3-tested for both oHCM and nHCM; and has been shown to reduce the risks for MI and stroke, although further clinical trials are probably warranted.
- While SGLT2 is detected only in kidney, SGLT1 is detected in guts, heart and brain.
I don't think BMY will ever recoup its investments in Camzyos. Inpefa covers wider HCM spectrum, once approved, would be a multi-
$B blockbuster!
2 replies